Available Technologies
# of Displayed Technologies: 4 / 4
Applied Category Filter (Click To Remove): Diagnostics
SARS-CoV-2 Diagnostic Assay with Sensors of Immune Activation
TS-050296 — A sequencing-based diagnostic assay for SARS-CoV-2 with sensors of immune activation and the viral microbiota.
Diagnosis of SARS-CoV-2 infection, which is responsible for COVID-19 disease, is typically performed by molecular analysis of upper respiratory sampling (e.g. nasal swab). Transcriptional-mediated amplification (TMA) and quantitative (real-time) polymerase chain reaction (qPCR) using one or more v…
- College: College of Medicine (COM)
- Inventors: Jones, Daniel; Avenarius, Matthew; Tu, Huolin
- Licensing Officer: Schworer, Adam
RNA Sequencing Assay to Detect Gene Fusion Mutations that Occur in Multiple Cancer Types
TS-038065 — OSU-SpARKFUSE is an RNA sequencing assay that detects known and novel gene fusion mutations in multiple cancer types.
Chromosomal rearrangements, leading to the juxtaposition of two unrelated genes and thus creating a chimeric mRNA transcript and protein ("gene fusions"), are important drivers of abnormal cell growth in cancers. Although gene fusions have a well-established role in hematologic malignanc…
- College: College of Medicine (COM)
- Inventors: Roychowdhury, Sameek
- Licensing Officer: Schworer, Adam
miRNA-based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy
TS-037521 — A method to use MiRNA to predict the likelihood of biochemical failure after radiation surgery.
The Need
Prostate cancer is one of the most common cancers worldwide, but current treatments can sometimes lead to complications. For example, radical prostatectomy is widely used for men in the early stages of prostate cancer, but long-term data shows that 30-40% of these patients experience bioch…
- College: College of Medicine (COM)
- Inventors: Chakravarti, Arnab; Bell, Erica
- Licensing Officer: Schworer, Adam
miR-3151 and BAALC as a Target for Drug Therapy
TS-014895 — Identified gene target for treatment of human acute leukemia, brain tumors and melanoma
Treatment failure is one of the leading causes of death in patients with human acute leukemia, yet the cause of treatment failure is still largely unknown. Overexpression of the RNA gene miR-3151 and its host gene, Brain and Acute Leukemia, Cytplasmic (BAALC), is a sign of an ineffective treatment…
- College: College of Medicine (COM)
- Inventors: de la Chapelle, Albert; Eisfeld, Ann-Kathrin; Tanner, Stephan
- Licensing Officer: Schworer, Adam
